Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus

Diabetes Educator

Volumn 32, Issue 6, 2006, Pages 869-876

  Koski, Renee Rae ^a  

^a FERRIS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

CLASSIFICATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 33750741441     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721706294260     Document Type: Review

References (35)

1. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
2. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2003;26(suppl 1):S28-S32.
3. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA. 2002;287:360-372.
4. Wickersham RM, Novak KK, eds. Drug Facts and Comparisons. St. Louis, Mo: Wolter Kluwer; 2006.
5. Average wholesale prices [Drugstore.com Web site]. Available at: www.drugstore.com/pharmacy/drugindex/. Accessed February 14, 2006.
6. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Metabolic and Endocrine Disorders Group. Cochrane Database Syst Rev. 2005;(3):CD002966.
7. Wulffele MG, Kooy A, De Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256:1-14.
8. Johnson JA, Simpson SH, Toth EL, et al. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med. 2005;22:497-502.
9. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137:25-33.
10. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med. 2003;163:2594-2602.
11. Glucophage. In: Physicians' Desk Reference [electronic version]. Greenwood Village, Colo: Thomson Micromedex; 2006.
12. Van der Laar FA, Lucassen PLBJ, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Metabolic and Endocrine Disorders Group. Cochrane Database Syst Rev. 2005;(2):CD003639.
13. Precose. In: Physicians' Desk Reference [electronic version]. Greenwood Village, Colo: Thomson Micromedex; 2006.
14. Glyset. In: Physicians' Desk Reference [electronic version]. Greenwood Village, Colo: Thomson Micromedex; 2006.
15. Shimabukuro M, Zhou Y-T, Lee Y, et al. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem. 1998;273:3547-3550.
16. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164:2097-2104.
17. Ahmann AJ, Riddle MC. Current oral agents for type 2 diabetes: many options, but which one to choose when? Postgrad Med. 2002;111:32-46.
18. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomized controlled trial. Lancet. 2005;366:1279-1289.
19. Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004;27:2654-2660.
20. Perfetti R, D'Amico E. Rational drug design and PPAR agonists. Curr Diabetes Rep. 2005;5:340-345.
21. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256-263.
22. Glitazone-associated macular edema. Pharmacist's Letter/Prescriber's Letter. 2006;22:220205.
23. Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf. 2001;24:873-888.
24. Avandia. In: Physicians' Desk Reference [electronic version]. Greenwood Village, Colo: Thomson Micromedex; 2006.
25. Actos. In: Physicians' Desk Reference [electronic version]. Greenwood Village, Colo: Thomson Micromedex; 2006.
26. Mitiglinide: KAD 1229, S 21403. Drugs R D. 2004;5:98-101.
27. Phillips LS, Dunning BE. Nateglinide (Starlix™): update on a new antihyperglycemic agent. Int J Clin Pract. 2003;57:535-541.
28. Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001;358:1709-1716.
29. Prandin. In: Physicians' Desk Reference [electronic version]. Greenwood Village, Colo: Thomson Micromedex; 2006.
30. Starlix. In: Physicians' Desk Reference [electronic version]. Greenwood Village, Colo: Thomson Micromedex; 2006.
31. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 40). JAMA. 1999;281:2005-2012.
32. Browne DL, Avery L, Turner BC, et al. What do patients with diabetes know about their tablets? Diabet Med. 2000;17:528-531.
33. Nielsen LL. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. DDT. 2005;10:703-710.
34. Sarabu R, Grimsby J. Targeting glucokinase activation for the treatment of type 2 diabetes - a status review. Curr Opin Drug Discov Devel. 2005;8:631-637.
35. Diabetes in Control.Com News and Information for Medical Professionals Issue #300. FDA accepts Merck's first in class drug application for JANUVIA™ for type 2. Available at: www.diabetes@topica.email-publisher. com. Accessed February 22, 2006.